Heat-shock protein 90 inhibitors as novel cancer chemotherapeutics – an update
- 1 February 2005
- journal article
- review article
- Published by Taylor & Francis in Emerging Drugs
- Vol. 10 (1) , 137-149
- https://doi.org/10.1517/14728214.10.1.137
Abstract
Heat-shock protein 90 (Hsp90) is a molecular chaperone whose association is required for stability and function of a growing number of signalling proteins that have been implicated in cancer cell s...Keywords
This publication has 69 references indexed in Scilit:
- Functional proteomic screens reveal an essential extracellular role for hsp90α in cancer cell invasivenessNature Cell Biology, 2004
- Induction of Hsp90 protein expression in malignant melanomas and melanoma metastasesExperimental Dermatology, 2004
- Geldanamycin, an inhibitor of Hsp90, sensitizes human tumour cells to radiationInternational Journal of Radiation Biology, 2003
- Geldanamycin inhibits migration of glioma cells in vitro: A potential role for hypoxia‐inducible factor (HIF‐1α) in glioma cell invasionJournal of Cellular Physiology, 2003
- Heat-shock protein 90 inhibitors as novel cancer chemotherapeutic agentsEmerging Drugs, 2002
- Akt Forms an Intracellular Complex with Heat Shock Protein 90 (Hsp90) and Cdc37 and Is Destabilized by Inhibitors of Hsp90 FunctionJournal of Biological Chemistry, 2002
- Hsp90 as a capacitor of phenotypic variationNature, 2002
- Hypoxia — a key regulatory factor in tumour growthNature Reviews Cancer, 2002
- The Hallmarks of CancerCell, 2000
- Von Hippel–Lindau disease maps to the region of chromosome 3 associated with renal cell carcinomaNature, 1988